세계의 불임 치료제 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

The global demand for Infertility Drugs Market is presumed to reach the market size of nearly USD 7.59 Billion by 2032 from USD 4.23 Billion in 2023 with a CAGR of 6.72% under the study period 2024-2032.

Infertility drugs are pharmaceutical treatments designed to address hormonal imbalances and reproductive issues that hinder conception. These medications aim to stimulate ovulation, improve sperm production, or regulate hormonal cycles, thereby increasing the chances of successful pregnancy. Common drugs include ovulation stimulants like clomiphene citrate and gonadotropins, which help induce ovulation in women, and medications like testosterone or hormone therapies for men to enhance sperm production. Additionally, some drugs target specific reproductive disorders or underlying conditions affecting fertility. By correcting hormonal deficiencies or improving reproductive function, these drugs play a crucial role in assisted reproductive treatments.

MARKET DYNAMICS

The rising prevalence of infertility, influenced by lifestyle factors, advanced age, and increasing rates of reproductive disorders, is a primary market driver. As more individuals and couples seek treatment options, the demand for effective infertility drugs is growing. Technological advancements and innovations in reproductive medicine present substantial opportunities for market expansion. The development of new and improved fertility drugs, including novel hormone therapies and targeted treatments, is enhancing the efficacy and safety of infertility management. These advancements enable more personalized treatment plans and higher success rates for fertility treatments. The increasing adoption of assisted reproductive technologies (ART) is also driving demand for infertility drugs. As ART procedures such as in vitro fertilization (IVF) become more prevalent, the need for supportive medications that optimize treatment outcomes and enhance fertility success is growing. Moreover, the expansion of fertility clinics and specialized reproductive health centers provides opportunities for increased drug utilization. These facilities offer comprehensive treatment options and personalized care, driving demand for a wide range of infertility medications. Public awareness campaigns and educational initiatives about infertility and available treatments contribute to market growth. As awareness increases, more individuals are seeking medical help and exploring drug-based solutions to address fertility challenges. However, high costs associated with infertility drugs and treatments, along with limited insurance coverage, may restrain market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Infertility Drugs. The growth and trends of Infertility Drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Infertility Drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

• Gonadotropins
• Aromatase Inhibitors
• Selective Estrogen Receptor Modulators (SERMs)
• Dopamine Agonists
• Others

By Distribution Channel

• Hospital Pharmacy
• Specialty & Retail Pharmacy
• Online Pharmacy

By End-user

• Men
• Women

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Infertility Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Infertility Drugs market include Merck & Co. Inc., Ferring B.V., Organon Group Of Companies, Abbott, Novartis AG, Bayer AG, Pfizer Inc., Mankind Pharma, Teva Pharmaceutical Industries Ltd., Sanofi. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. INFERTILITY DRUGS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Drug Class
  • 3.7.2 Market Attractiveness Analysis By Distribution Channel
  • 3.7.3 Market Attractiveness Analysis By End-user
  • 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL INFERTILITY DRUGS MARKET ANALYSIS BY DRUG CLASS

• 5.1. Overview By Drug Class
• 5.2. Historical and Forecast Data Analysis By Drug Class
• 5.3. Gonadotropins Historic and Forecast Sales By Regions
• 5.4. Aromatase Inhibitors Historic and Forecast Sales By Regions
• 5.5. Selective Estrogen Receptor Modulators (SERMs) Historic and Forecast Sales By Regions
• 5.6. Dopamine Agonists Historic and Forecast Sales By Regions
• 5.7. Others Historic and Forecast Sales By Regions

6. GLOBAL INFERTILITY DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 6.1. Overview By Distribution Channel
• 6.2. Historical and Forecast Data Analysis By Distribution Channel
• 6.3. Hospital Pharmacy Historic and Forecast Sales By Regions
• 6.4. Specialty & Retail Pharmacy Historic and Forecast Sales By Regions
• 6.5. Online Pharmacy Historic and Forecast Sales By Regions

7. GLOBAL INFERTILITY DRUGS MARKET ANALYSIS BY END-USER

• 7.1. Overview By End-user
• 7.2. Historical and Forecast Data Analysis By End-user
• 7.3. Men Historic and Forecast Sales By Regions
• 7.4. Women Historic and Forecast Sales By Regions

8. GLOBAL INFERTILITY DRUGS MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2 North America By Segment Sales Analysis
  • 8.3.3 North America By Country Sales Analysis
  • 8.3.4 United States Sales Analysis
  • 8.3.5 Canada Sales Analysis
  • 8.3.6 Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2 Europe By Segment Sales Analysis
  • 8.4.3 Europe By Country Sales Analysis
  • 8.4.4 United Kingdom Sales Analysis
  • 8.4.5 France Sales Analysis
  • 8.4.6 Germany Sales Analysis
  • 8.4.7 Italy Sales Analysis
  • 8.4.8 Russia Sales Analysis
  • 8.4.9 Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2 Asia Pacific By Segment Sales Analysis
  • 8.5.3 Asia Pacific By Country Sales Analysis
  • 8.5.4 China Sales Analysis
  • 8.5.5 India Sales Analysis
  • 8.5.6 Japan Sales Analysis
  • 8.5.7 South Korea Sales Analysis
  • 8.5.8 Australia Sales Analysis
  • 8.5.9 South East Asia Sales Analysis
  • 8.5.10 Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2 Latin America By Segment Sales Analysis
  • 8.6.3 Latin America By Country Sales Analysis
  • 8.6.4 Brazil Sales Analysis
  • 8.6.5 Argentina Sales Analysis
  • 8.6.6 Peru Sales Analysis
  • 8.6.7 Chile Sales Analysis
  • 8.6.8 Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2 Middle East & Africa By Segment Sales Analysis
  • 8.7.3 Middle East & Africa By Country Sales Analysis
  • 8.7.4 Saudi Arabia Sales Analysis
  • 8.7.5 UAE Sales Analysis
  • 8.7.6 Israel Sales Analysis
  • 8.7.7 South Africa Sales Analysis
  • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE INFERTILITY DRUGS COMPANIES

• 9.1. Infertility Drugs Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10. COMPANY PROFILES OF INFERTILITY DRUGS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Market Concentration Rate
• 10.3. Merck & Co. Inc.
  • 10.3.1 Company Overview
  • 10.3.2 Company Revenue
  • 10.3.3 Products
  • 10.3.4 Recent Developments
• 10.4. Ferring B.V.
  • 10.4.1 Company Overview
  • 10.4.2 Company Revenue
  • 10.4.3 Products
  • 10.4.4 Recent Developments
• 10.5. Organon Group Of Companies
  • 10.5.1 Company Overview
  • 10.5.2 Company Revenue
  • 10.5.3 Products
  • 10.5.4 Recent Developments
• 10.6. Abbott
  • 10.6.1 Company Overview
  • 10.6.2 Company Revenue
  • 10.6.3 Products
  • 10.6.4 Recent Developments
• 10.7. Novartis AG
  • 10.7.1 Company Overview
  • 10.7.2 Company Revenue
  • 10.7.3 Products
  • 10.7.4 Recent Developments
• 10.8. Bayer AG
  • 10.8.1 Company Overview
  • 10.8.2 Company Revenue
  • 10.8.3 Products
  • 10.8.4 Recent Developments
• 10.9. Pfizer Inc.
  • 10.9.1 Company Overview
  • 10.9.2 Company Revenue
  • 10.9.3 Products
  • 10.9.4 Recent Developments
• 10.10. Mankind Pharma
  • 10.10.1 Company Overview
  • 10.10.2 Company Revenue
  • 10.10.3 Products
  • 10.10.4 Recent Developments
• 10.11. Teva Pharmaceutical Industries Ltd.
  • 10.11.1 Company Overview
  • 10.11.2 Company Revenue
  • 10.11.3 Products
  • 10.11.4 Recent Developments
• 10.12. Sanofi
  • 10.12.1 Company Overview
  • 10.12.2 Company Revenue
  • 10.12.3 Products
  • 10.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies